Cargando…

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects

Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately, the development of drug resistance to sorafen...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Weiwei, Chen, Ziyi, Zhang, Wenling, Cheng, Ye, Zhang, Betty, Wu, Fan, Wang, Qian, Wang, Shouju, Rong, Dawei, Reiter, F. P., De Toni, E. N., Wang, Xuehao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292831/
https://www.ncbi.nlm.nih.gov/pubmed/32532960
http://dx.doi.org/10.1038/s41392-020-0187-x
_version_ 1783546176935559168
author Tang, Weiwei
Chen, Ziyi
Zhang, Wenling
Cheng, Ye
Zhang, Betty
Wu, Fan
Wang, Qian
Wang, Shouju
Rong, Dawei
Reiter, F. P.
De Toni, E. N.
Wang, Xuehao
author_facet Tang, Weiwei
Chen, Ziyi
Zhang, Wenling
Cheng, Ye
Zhang, Betty
Wu, Fan
Wang, Qian
Wang, Shouju
Rong, Dawei
Reiter, F. P.
De Toni, E. N.
Wang, Xuehao
author_sort Tang, Weiwei
collection PubMed
description Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately, the development of drug resistance to sorafenib is becoming increasingly common. This study aims to identify factors contributing to resistance and ways to mitigate resistance. Recent studies have shown that epigenetics, transport processes, regulated cell death, and the tumor microenvironment are involved in the development of sorafenib resistance in HCC and subsequent HCC progression. This study summarizes discoveries achieved recently in terms of the principles of sorafenib resistance and outlines approaches suitable for improving therapeutic outcomes for HCC patients.
format Online
Article
Text
id pubmed-7292831
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72928312020-06-19 The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects Tang, Weiwei Chen, Ziyi Zhang, Wenling Cheng, Ye Zhang, Betty Wu, Fan Wang, Qian Wang, Shouju Rong, Dawei Reiter, F. P. De Toni, E. N. Wang, Xuehao Signal Transduct Target Ther Review Article Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC), sorafenib is currently an effective first-line therapy. Unfortunately, the development of drug resistance to sorafenib is becoming increasingly common. This study aims to identify factors contributing to resistance and ways to mitigate resistance. Recent studies have shown that epigenetics, transport processes, regulated cell death, and the tumor microenvironment are involved in the development of sorafenib resistance in HCC and subsequent HCC progression. This study summarizes discoveries achieved recently in terms of the principles of sorafenib resistance and outlines approaches suitable for improving therapeutic outcomes for HCC patients. Nature Publishing Group UK 2020-06-10 /pmc/articles/PMC7292831/ /pubmed/32532960 http://dx.doi.org/10.1038/s41392-020-0187-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Tang, Weiwei
Chen, Ziyi
Zhang, Wenling
Cheng, Ye
Zhang, Betty
Wu, Fan
Wang, Qian
Wang, Shouju
Rong, Dawei
Reiter, F. P.
De Toni, E. N.
Wang, Xuehao
The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
title The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
title_full The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
title_fullStr The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
title_full_unstemmed The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
title_short The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
title_sort mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292831/
https://www.ncbi.nlm.nih.gov/pubmed/32532960
http://dx.doi.org/10.1038/s41392-020-0187-x
work_keys_str_mv AT tangweiwei themechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT chenziyi themechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT zhangwenling themechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT chengye themechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT zhangbetty themechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT wufan themechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT wangqian themechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT wangshouju themechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT rongdawei themechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT reiterfp themechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT detonien themechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT wangxuehao themechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT tangweiwei mechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT chenziyi mechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT zhangwenling mechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT chengye mechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT zhangbetty mechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT wufan mechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT wangqian mechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT wangshouju mechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT rongdawei mechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT reiterfp mechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT detonien mechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects
AT wangxuehao mechanismsofsorafenibresistanceinhepatocellularcarcinomatheoreticalbasisandtherapeuticaspects